H. Kakinuma

发表

Development of a Method for Evaluating Drug‐Likeness and Ease of Synthesis Using a Data Set in which Compounds Are Assigned Scores Based on Chemists′ Intuition.

Susumu Yamanobe, Yuji Takaoka, Taketoshi Okubo, 2003 .

Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.

Toshio Nakamura, H. Kakinuma, N. Miyata, 2004, Bioorganic & medicinal chemistry letters.

Synthesis and antifungal activity of novel thiazole-containing triazole antifungals.

A. Tsuruoka, T. Naito, H. Kakinuma, 1997, Chemical & pharmaceutical bulletin.

Construction of C-glucoside in SGLT2 Inhibitors

H. Kakinuma, Takahiro Oi, 2016 .

Discovery of novel 2-[(4-hydroxy-6-oxo-2,3-dihydro-1H-pyridine-5-carbonyl)amino]acetic acid derivatives as HIF prolyl hydroxylase inhibitors for treatment of renal anemia.

H. Kakinuma, Sota Kato, Hiroki Takano, 2018, Bioorganic & medicinal chemistry letters.

Efficient screening for catalytic antibodies using a short transition-state analog and detailed characterization of selected antibodies.

H. Kakinuma, Y. Nishi, H. Matsushita, 1999, European journal of biochemistry.

(1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment.

H. Kakinuma, F. Io, Saeko Uchida, 2010, Journal of medicinal chemistry.

Design, synthesis and biological evaluation of novel 7-azaspiro[3.5]nonane derivatives as GPR119 agonists.

H. Kakinuma, Noriko Takayama, Fumiyasu Shiozawa, 2018, Bioorganic & medicinal chemistry.

Novel 3H-[1,2,3]triazolo[4,5-c]pyridine derivatives as GPR119 agonists: Synthesis and structure-activity/solubility relationships.

H. Kakinuma, Noriko Takayama, Fumiyasu Shiozawa, 2017, Bioorganic & medicinal chemistry.

Discovery of Aryloxyphenyl-Heptapeptide Hybrids as Potent and Selective Matrix Metalloproteinase-2 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis.

H. Kakinuma, Akiko Nozoe, Y. Kato, 2022, Journal of medicinal chemistry.

Molecular Evolution of Catalytic Antibodies

H. Kakinuma, Y. Nishi, N. Takahashi, 2001 .

Synthesis and antifungal activity of novel thiazole-containing triazole antifungals.

A. Tsuruoka, T. Naito, H. Kakinuma, 1997, Chemical & pharmaceutical bulletin.

The preparation and crystallization of Fab fragments of a family of mouse esterolytic catalytic antibodies and their complexes with a transition-state analogue.

D. Rice, A. Moir, S. Sedelnikova, 2001, Acta crystallographica. Section D, Biological crystallography.

Ab initio study toward designing transition‐state analogues which elicit proteolytic catalytic antibodies

H. Kakinuma, K. Sakakibara, Y. Nishi, 2000 .

Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.

Toshio Nakamura, H. Kakinuma, N. Miyata, 2003, Journal of medicinal chemistry.

Synthesis and antifungal activity of novel thiazole-containing triazole antifungals. II. Optically active ER-30346 and its derivatives.

A. Tsuruoka, T. Naito, H. Kakinuma, 1998, Chemical & pharmaceutical bulletin.

Comparison of phosphonate transition state analogs for inducing catalytic antibodies and evaluation of key structural factors by an ab initio study

H. Kakinuma, Y. Nishi, H. Matsushita, 1999 .

Design, synthesis and biological evaluation of novel indole derivatives as gut-selective NaPi2b inhibitors.

H. Kakinuma, Mayumi Endo, Teisuke Takahashi, 2022, Bioorganic & medicinal chemistry.

Design, synthesis and biological evaluation of novel pyridine derivatives as gut-selective NaPi2b inhibitors.

H. Kakinuma, Mayumi Endo, Teisuke Takahashi, 2022, Bioorganic & medicinal chemistry letters.

Design, synthesis and biological evaluation of novel 1H-pyrazole-4-carbonyl-4,5,6,7-tetrahydrobenzo [b]thiophene derivatives as gut-selective NaPi2b inhibitors.

H. Kakinuma, Mayumi Endo, Teisuke Takahashi, 2022, Bioorganic & medicinal chemistry letters.

A Novel Route for Chiral Synthesis of the Triazole Antifungal ER-30346

A. Tsuruoka, T. Naito, H. Kakinuma, 1998 .

Synthesis of 1',6'-disubstituted sucroses and their behavior as glucosyl donors for a microbial alpha-glucosyltransferase.

H. Kakinuma, H. Hashimoto, H. Yuasa, 1996, Carbohydrate research.

Transglucosylation with 6'-chloro-6'-deoxysucrose and immobilized isomaltulose-producing microorganisms using 2,2-dimethyl-1,3-dioxolane-4-methanol and its related compounds as acceptors. Steric and chemical requirement of the glucosyl acceptor.

H. Kakinuma, M. Tanaka, H. Hashimoto, 1994, Carbohydrate research.

In vitro abzyme evolution to optimize antibody recognition for catalysis

Ikuo Fujii, I. Fujii, H. Kakinuma, 2001, Nature Biotechnology.

High-resolution crystal structure of the Fab-fragments of a family of mouse catalytic antibodies with esterase activity.

D. Rice, S. Sedelnikova, I. Murray, 2003, Journal of molecular biology.

Catalytic antibodies in autoimmune mice.

J. Sun, H. Kakinuma, Y. Nishi, 2000, Chemical immunology.

Directed evolution governed by controlling the molecular recognition between an abzyme and its haptenic transition-state analog.

N. Takahashi-Ando, I. Fujii, H. Kakinuma, 2004, Journal of immunological methods.

Molecular Evolution of Catalytic Antibodies in Autoimmune Mice1

H. Kakinuma, Y. Nishi, N. Takahashi, 2001, The Journal of Immunology.

This information is current as in Autoimmune Mice Molecular Evolution of Catalytic Antibodies

H. Kakinuma, Y. Nishi, N. Takahashi, 2001 .

Improved generation of catalytic antibodies by MRL/MPJ-lpr/lpr autoimmune mice.

H. Kakinuma, Y. Nishi, H. Matsushita, 2000, Journal of immunological methods.

Development of a Method for Evaluating Drug-Likeness and Ease of Synthesis Using a Data Set in Which Compounds Are Assigned Scores Based on Chemists' Intuition

Yutaka Endo, Susumu Yamanobe, Yuji Takaoka, 2003, J. Chem. Inf. Comput. Sci..

Selective chemotherapeutic strategies using catalytic antibodies: a common pro-moiety for antibody-directed abzyme prodrug therapy.

I. Fujii, H. Kakinuma, Y. Nishi, 2002, Journal of immunological methods.

Structure-activity relationships of novel piperazines as antagonists for the melanocortin-4 receptor.

Shigeru Okuyama, Taketoshi Okubo, S. Chaki, 2007, Bioorganic & medicinal chemistry.

Glycosyltransfer mechanism of α-glucosyltransferase from Protaminobacter rubrum

H. Kakinuma, H. Hashimoto, H. Yuasa, 1998 .

Lead identification of novel tetrahydroimidazo[1,2-a]pyridine-5-carboxylic acid derivative as a potent heparanase-1 inhibitor.

Sayaka Kato, H. Kakinuma, Sota Kato, 2022, Bioorganic & medicinal chemistry letters.

Mechanistic analysis of the phosphonate transition-state analogue-derived catalytic and non-catalytic antibody.

D. Rice, N. Takahashi-Ando, S. Ruzheinikov, 2007, Journal of biochemistry.

Discovery of TP0597850: A Selective, Chemically Stable, and Slow Tight-Binding Matrix Metalloproteinase-2 Inhibitor with a Phenylbenzamide-Pentapeptide Hybrid Scaffold.

H. Kakinuma, Akiko Nozoe, Y. Nomura, 2023, Journal of medicinal chemistry.

Discovery of Novel Pyrazolylpyridine Derivatives for 20-Hydroxyeicosatetraenoic Acid Synthase Inhibitors with Selective CYP4A11/4F2 Inhibition.

H. Kakinuma, Hiroko Koretsune, Yuji Ito, 2022, Journal of medicinal chemistry.

Design and synthesis of 1H-pyrazolo[3,4-c]pyridine derivatives as a novel structural class of potent GPR119 agonists.

H. Kakinuma, Noriko Takayama, Fumiyasu Shiozawa, 2016, Bioorganic & medicinal chemistry letters.

Pyrazole derivatives as new potent and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.

Toshio Nakamura, H. Kakinuma, N. Miyata, 2004, Bioorganic & medicinal chemistry.

Discovery of a novel tetrahydroimidazo[1,2-a]pyridine-5-carboxylic acid derivative as a potent and selective heparanase-1 inhibitor utilizing an improved synthetic approach.

H. Kakinuma, Takuya Fukunaga, R. Tabata, 2023, Bioorganic & medicinal chemistry letters.

Structure-based lead optimization to improve potency and selectivity of a novel tetrahydroimidazo[1,2-a]pyridine-5-carboxylic acid series of heparanase-1 inhibitor.

H. Kakinuma, H. Miyagawa, Mayumi Endo, 2023, Bioorganic & medicinal chemistry.

Lead generation from N-[benzyl(4-phenylbutyl)carbamoyl]amino acid as a novel LPA1 antagonist for the treatment of systemic sclerosis.

H. Kakinuma, Reiko Wada, Hidetoh Toki, 2023, European journal of medicinal chemistry.